Loading...
XNAS
MREO
Market cap53mUSD
Jul 10, Last price  
1.69USD
1D
-42.52%
1Q
-13.33%
IPO
-71.45%
Name

Mereo Biopharma Group PLC

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
52.58%
Rev. gr., 5y
%
Revenues
0k
-100.00%
0-3,285,2940-122,000393,00036,464,0001,507,00010,000,0000
Net income
-43m
L+46.79%
-28,390,280-38,799,054-32,028,740-34,844,000-163,628,00012,725,000-34,196,000-29,466,000-43,253,000
CFO
-33m
L+55.38%
-27,399,548-32,147,971-23,137,113-45,931,000-28,341,000-5,239,000-38,820,000-21,132,000-32,834,000

Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
IPO date
Jun 09, 2016
Employees
36
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
10,000
563.57%
1,507
-95.87%
Cost of revenue
47,364
38,416
45,441
Unusual Expense (Income)
NOPBT
(47,364)
(28,416)
(43,934)
NOPBT Margin
Operating Taxes
(532)
(1,897)
Tax Rate
NOPAT
(47,364)
(27,884)
(42,037)
Net income
(43,253)
46.79%
(29,466)
-13.83%
(34,196)
-368.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
47,000
11,605
BB yield
Debt
Debt current
707
652
11,551
Long-term debt
1,081
6,858
2,910
Deferred revenue
Other long-term liabilities
1,386
1,176
311
Net debt
(68,014)
(49,911)
(41,873)
Cash flow
Cash from operating activities
(32,834)
(21,132)
(38,820)
CAPEX
(10)
Cash from investing activities
(699)
(419)
1,497
Cash from financing activities
46,147
7,973
(784)
FCF
(46,698)
(27,703)
(41,338)
Balance
Cash
69,802
57,421
56,334
Long term investments
Excess cash
69,802
56,921
56,259
Stockholders' equity
(478,673)
(434,340)
(191,377)
Invested Capital
541,922
492,005
266,162
ROIC
ROCE
EV
Common stock shares outstanding
739,624
659,454
603,196
Price
Market cap
EV
EBITDA
(46,783)
(27,355)
(43,207)
EV/EBITDA
Interest
1,370
2,881
3,361
Interest/NOPBT